Prevalence of cirrhosis & portal hypertension in U.S.

According to the latest prevalence data from 2018, 4.5 million U.S. adults are diagnosed with chronic liver disease. Late stage liver disease, or cirrhosis, affects 1 in 400 adults. Chronic liver disease was the 10th leading cause of death in the U.S. in 20221. Today there is updated guidance and newer evidence on treatment options for advanced liver disease that help increase survival for patients with late-stage, chronic liver disease.

Prevalence of cirrhosis & portal hypertension in U.S.

Consider earlier TIPS when treating portal hypertension.

Advanced by compelling evidence, earlier transjugular intrahepatic portosystemic shunt (TIPS) procedures are helping physicians increase survival in high-risk liver disease patients.
Higher transplant-free survival for recurrent ascites at 1 year†,4
Higher survival in Child-Pugh C patients with acute variceal bleeding (AVB) at 1 year‡,5

93% TIPS

vs. 52% large-volume paracenteses (LVP) +albumin (A) (P =.003)

78% TIPS

vs. 53% pharmacotherapy + endoscopic band ligation (EBL) (P =.002)
Read about earlier TIPS for ascites and variceal bleeding

* 1 in 400 U.S. adults (340.1 m) have cirrhosis.

† Early TIPS (n = 29) compared to large-volume paracenteses and albumin infusion (LVP+A) (n = 33).

‡ Early TIPS (n = 66) compared to pharmacotherapy+endoscopic band ligation (EBL) (n = 605). Child-Pugh C patients with scores < 14.

  1. Centers for Disease Control and Prevention. (CDC). Accessed April 3, 2025. www.cdc.gov
  2. National Institutes of Health (NIH). Accessed April 3, 2025. www.nih.gov
  3. Portal hypertension. Cleveland Clinic. Updated October 2, 2022. Accessed April 8, 2025. www.my.clevelandclinic.org/health/diseases/4912-portal-hypertension
  4. Bureau C, Thabut D, Oberti D, et al.  Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology 2017;152(1):157-163. http://www.sciencedirect.com/science/article/pii/S0016508516351101
  5. Hernández-Gea V, Procopet B, Giráldez Á, et al; International Variceal Bleeding Observational Study Group and Baveno Cooperation. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study. Hepatology 2019;69(1):282-293. https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.30182 
IFU Consult instructions

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

INDICATIONS FOR USE IN THE U.S.: The GORE® VIATORR® TIPS Endoprosthesis is indicated for use in the de novo and revision treatment of portal hypertension and its complications such as variceal bleeding, gastropathy, ascites which recurs despite conventional treatment, and / or hepatic hydrothorax.

CONTRAINDICATIONS: There are no known contraindications for this device.

25PL1042-EN01